Verona Wins FDA Approval for COPD Drug, Eyes Q3 Launch With $1B Financing for Rollout 6/27/2024

Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss 6/27/2024

AbbVie, Genmab Secure FDA Label Expansion for Epkinly in Follicular Lymphoma 6/27/2024

CDC Narrows RSV Vaccine Recommendations for Seniors 6/27/2024

New Team, Same Company: How to Transition to Your New Role 6/27/2024

Leadership Lab: 3 Strategies for an Executive’s Discreet Job Search 6/27/2024

5 Top Companies Hiring in the Washington, D.C., Area 6/27/2024

AlphaFold is an outstanding example of artificial intelligence's computational capabilities in accurately predicting intricate protein structures. A new Review article explores AlphaFold's recent advancements and its potential impact on predictive medicine. The article is published in the peer-reviewed journal AI in Precision Oncology.

Vivek Subbiah, MD, from the Sarah Cannon Research Institute, and coauthors, describe a shift toward predictive medicine,

Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate 6/26/2024

Zealand to Raise $1B in Public Offering to Fund Obesity Candidates 6/26/2024

Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic 6/26/2024

Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria 6/26/2024

Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval 6/26/2024

Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade 6/26/2024

How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs 6/26/2024

Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights 6/26/2024

After Full Approval, Sarepta Lays Out Its Next Moves 6/26/2024

Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good 6/26/2024

Bayer AG, together with Charité - Universitätsmedizin Berlin, presented plans for the construction of the Berlin Center for Gene and Cell Therapies. The project is being substantially financed and supported by Germany's Federal Government as well as the State of Berlin. The aim of the joint project is to bring these groundbreaking technologies to patients more quickly while creating a leading biotech ecosystem for innovative therapies in Berlin.

A new AI-powered program will allow researchers to level up their drug discovery efforts.

The program, called TopoFormer, was developed by an interdisciplinary team led by Guowei Wei, a Michigan State University Research Foundation Professor in the Department of Mathematics. TopoFormer translates three-dimensional information about molecules into data that typical AI-based drug-interaction models can use, expanding those models' abilities to predict how effective a drug might be.